Global Parkinson’s Disease Market Report: 2016 Edition
Parkinson’s Disease (PD) is a chronic and progressive neurodegenerative or movement disorder which involves the malfunction and death of vital nerve cells in the brain, called neurons. Parkinson’s primarily affects neurons in an area of the brain called the “substantia nigra”. The early signs and symptoms may be mild and may go unnoticed initially. The cause of this disease is mainly unknown with no cure till date but there exist several treatment options such as medications and surgery.
The current treatment market for Parkinson’s disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinson’s disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinson’s along with possibility of developing “Stem Cell” as a treatment therapy.
The Parkinson’s disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinson’s disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.
The report, “Global Parkinson’s disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.
The current treatment market for Parkinson’s disease has several unmet needs as no treatment has yet been successful in fully restoring the function that produces dopamine. However, the treatment currently only aims at controlling and relieving symptoms. The Parkinson’s disease treatment market remains flooded by both branded and generic drugs. The market is expected to experience fluctuations in branded sales due to patent expiries and subsequent entry of generics in the market. Several biologics are under development for the treatment of Parkinson’s along with possibility of developing “Stem Cell” as a treatment therapy.
The Parkinson’s disease market is expected to acquire modest growth driven by launch of new therapies and increasing rate of drug treatment due to increasing healthcare expenditure and ageing population. The major growth drivers of the Parkinson’s disease market includes rising level of toxin exposure, increasing life expectancy, rising male population worldwide, ageing population, healthcare expenditure and pesticide consumption. However, the growth of the market will also remain challenged by generic erosion, current treatment limitations and increasing risk of developing Melanoma.
The report, “Global Parkinson’s disease Market” analyzes the currently prevailing condition of the market along with its future scope of development. The specific markets of the U.S., the European Union and Japan are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.
1. MARKET OVERVIEW
1.1 Introduction
1.2 Fundamental Features
1.3 Types of Parkinson’s Disease
1.4 Risk Factors
1.5 Treatment Options
2. GLOBAL MARKET
2.1 Global Parkinson’s Disease Drug Market by Value
2.1.1 Global Parkinson’s Disease Drug Market by Region
2.1.2 Global Parkinson’s Disease Market by Drug Class
2.1.3 Global Parkinson’s Disease Patient Population by Severity
2.1.4 Global Parkinson’s Disease Patient Population by Region
3. REGIONAL MARKETS
3.1 The U.S.
3.1.1 The U.S. Parkinson’s Disease Market by Value & Volume
3.1.2 The U.S. Parkinson’s Disease Market Value by Category
3.1.3 The U.S. Parkinson’s Disease Market Volume by Category
3.1.4 The U.S. Parkinson’s Disease Market by Drug Class
3.1.5 The U.S. Parkinson’s Disease Branded Drugs Market
3.1.6 The U.S. Parkinson’s Disease Generic Drugs Market
3.2 The European Union
3.2.1 The E.U. Parkinson’s Patient Prevalence & Diagnosis
3.2.2 The European Parkinson’s Disease Drug Market by Value
3.3 Japan
3.3.1 Japan’s Parkinson’s Disease Drug Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Level of Toxin Exposure
4.1.2 Rising Life Expectancy
4.1.3 Rising Male Population
4.1.4 Increasing Ageing Population
4.1.5 Global Healthcare Expenditure
4.1.6 Pesticides Consumption
4.2 Trends
4.2.1 Late-Stage Drug Development for Parkinson’s Disease
4.2.2 Stem-Cell Therapy as Potential Treatment
4.2.3 Biologics under Development for Parkinson’s Disease
4.3 Challenges
4.3.1 Generic Erosion
4.3.2 Parkinson’s Treatment associated with Higher Risk of Melanoma
4.3.3 Current Treatment Limitation
5. COMPETITIVE LANDSCAPE
5.1 The U.S. Parkinson’s Disease Branded Drug Market by Company
5.2 The U.S. Parkinson’s Disease Generic Drug Market by Company
6. COMPANY PROFILES
6.1 Biotie Therapies Corp.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Adamas Pharmaceuticals Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Lundbeck
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
7. MARKET OUTLOOK
7.1 Global Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
1.1 Introduction
1.2 Fundamental Features
1.3 Types of Parkinson’s Disease
1.4 Risk Factors
1.5 Treatment Options
2. GLOBAL MARKET
2.1 Global Parkinson’s Disease Drug Market by Value
2.1.1 Global Parkinson’s Disease Drug Market by Region
2.1.2 Global Parkinson’s Disease Market by Drug Class
2.1.3 Global Parkinson’s Disease Patient Population by Severity
2.1.4 Global Parkinson’s Disease Patient Population by Region
3. REGIONAL MARKETS
3.1 The U.S.
3.1.1 The U.S. Parkinson’s Disease Market by Value & Volume
3.1.2 The U.S. Parkinson’s Disease Market Value by Category
3.1.3 The U.S. Parkinson’s Disease Market Volume by Category
3.1.4 The U.S. Parkinson’s Disease Market by Drug Class
3.1.5 The U.S. Parkinson’s Disease Branded Drugs Market
3.1.6 The U.S. Parkinson’s Disease Generic Drugs Market
3.2 The European Union
3.2.1 The E.U. Parkinson’s Patient Prevalence & Diagnosis
3.2.2 The European Parkinson’s Disease Drug Market by Value
3.3 Japan
3.3.1 Japan’s Parkinson’s Disease Drug Market by Value
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Rising Level of Toxin Exposure
4.1.2 Rising Life Expectancy
4.1.3 Rising Male Population
4.1.4 Increasing Ageing Population
4.1.5 Global Healthcare Expenditure
4.1.6 Pesticides Consumption
4.2 Trends
4.2.1 Late-Stage Drug Development for Parkinson’s Disease
4.2.2 Stem-Cell Therapy as Potential Treatment
4.2.3 Biologics under Development for Parkinson’s Disease
4.3 Challenges
4.3.1 Generic Erosion
4.3.2 Parkinson’s Treatment associated with Higher Risk of Melanoma
4.3.3 Current Treatment Limitation
5. COMPETITIVE LANDSCAPE
5.1 The U.S. Parkinson’s Disease Branded Drug Market by Company
5.2 The U.S. Parkinson’s Disease Generic Drug Market by Company
6. COMPANY PROFILES
6.1 Biotie Therapies Corp.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Adamas Pharmaceuticals Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Lundbeck
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
7. MARKET OUTLOOK
7.1 Global Market Forecast
7.2 Forecast Methodology
7.2.1 Dependent and Independent Variables
7.2.2 Correlation Analysis
7.2.3 Regression Analysis
LIST OF CHARTS
Global Parkinson’s Disease Drug Market by Value (2010-2015E)
Global Parkinson’s Disease Drug Market by Region (2014)
Global Parkinson’s Disease Market by Drug Class (2015E)
Global Parkinson’s Disease Patient Population by Severity (2015E)
Global Parkinson’s Disease Patient Population by Region (2015E)
The U.S. Parkinson’s Disease Market by Value & Volume (2013-2020E)
The U.S. Parkinson’s Disease Market Value by Category (2013-2017E)
The U.S. Parkinson’s Disease Market Volume by Category (2015)
The U.S. Parkinson’s Disease Market by Drug Class (2015)
The U.S. Parkinson’s Branded Drugs Market by Value & Volume (2013-2020E)
The U.S. Parkinson’s Generic Drugs Market by Value & Volume (2013-2020E)
The E.U. Parkinson’s Disease Prevalence and Diagnosis (2013-2018E)
The European Parkinson’s Disease Drug Market by Value (2014/2015)
Japan’s Parkinson’s Disease Drug Market by Value (2014/2015)
Global Lead Production (2000-2014)
Global Life Expectancy at Birth (2008-2014E)
Global Male Population (2009-2014)
Global Ageing Population above 65 Years (2009-2014)
Global Healthcare Expenditure (2009-2014)
The U.S Parkinson’s Disease Branded Market by Drug (2015)
The U.S. Parkinson’s Disease Generic Market by Drug (2015)
Portfolio of Innovative CNS Medicines
Biotie Therapies Corp Revenue & Net Income/Loss (2011-2015)
Biotie’s Research and Development Expenditure (2011-2015)
Adamas Pharmaceuticals Revenue and Net Income/Loss (2012-2015)
Adamas Pharmaceutical’s R&D Expenditure (2012-2015)
Lundbeck’s Revenue Share by Product (2014)
Lundbeck’s Revenue Share by Region (2014)
Lundbeck’s Revenue and Annual Growth (2012-2017E)
Novartis Revenue by Business Segments (2015)
Novartis Revenue and Net Income (2011-2015)
Global Parkinson’s Disease Market Forecast (2013-2017F)
Global Parkinson’s Disease Drug Market by Value (2010-2015E)
Global Parkinson’s Disease Drug Market by Region (2014)
Global Parkinson’s Disease Market by Drug Class (2015E)
Global Parkinson’s Disease Patient Population by Severity (2015E)
Global Parkinson’s Disease Patient Population by Region (2015E)
The U.S. Parkinson’s Disease Market by Value & Volume (2013-2020E)
The U.S. Parkinson’s Disease Market Value by Category (2013-2017E)
The U.S. Parkinson’s Disease Market Volume by Category (2015)
The U.S. Parkinson’s Disease Market by Drug Class (2015)
The U.S. Parkinson’s Branded Drugs Market by Value & Volume (2013-2020E)
The U.S. Parkinson’s Generic Drugs Market by Value & Volume (2013-2020E)
The E.U. Parkinson’s Disease Prevalence and Diagnosis (2013-2018E)
The European Parkinson’s Disease Drug Market by Value (2014/2015)
Japan’s Parkinson’s Disease Drug Market by Value (2014/2015)
Global Lead Production (2000-2014)
Global Life Expectancy at Birth (2008-2014E)
Global Male Population (2009-2014)
Global Ageing Population above 65 Years (2009-2014)
Global Healthcare Expenditure (2009-2014)
The U.S Parkinson’s Disease Branded Market by Drug (2015)
The U.S. Parkinson’s Disease Generic Market by Drug (2015)
Portfolio of Innovative CNS Medicines
Biotie Therapies Corp Revenue & Net Income/Loss (2011-2015)
Biotie’s Research and Development Expenditure (2011-2015)
Adamas Pharmaceuticals Revenue and Net Income/Loss (2012-2015)
Adamas Pharmaceutical’s R&D Expenditure (2012-2015)
Lundbeck’s Revenue Share by Product (2014)
Lundbeck’s Revenue Share by Region (2014)
Lundbeck’s Revenue and Annual Growth (2012-2017E)
Novartis Revenue by Business Segments (2015)
Novartis Revenue and Net Income (2011-2015)
Global Parkinson’s Disease Market Forecast (2013-2017F)
LIST OF TABLES
Currently Leading Treatment Drugs for Parkinson’s Disease
Selected Late-Stage Drugs for Parkinson’s
Selected Late-Stage Drugs for Parkinson’s Disease
Biologics under Development for Parkinson’s Disease
Adamas Pharmaceuticals Therapeutic Portfolio
Lundbeck’s Product Pipeline
Dependent and Independent Variable
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
Currently Leading Treatment Drugs for Parkinson’s Disease
Selected Late-Stage Drugs for Parkinson’s
Selected Late-Stage Drugs for Parkinson’s Disease
Biologics under Development for Parkinson’s Disease
Adamas Pharmaceuticals Therapeutic Portfolio
Lundbeck’s Product Pipeline
Dependent and Independent Variable
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output
